Moderna Reports Third Quarter 2024 Financial Results and Provides Business Updates
Portfolio Pulse from
Moderna reported Q3 2024 revenues of $1.9 billion and a net income of $13 million. The company reiterated its 2024 product sales forecast of $3.0 to $3.5 billion. Moderna also initiated Phase 3 trials for mRNA vaccines against norovirus and influenza and expanded its Executive Committee.
November 07, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Moderna reported Q3 2024 revenues of $1.9 billion and a net income of $13 million, with a positive EPS of $0.03. The company reiterated its 2024 product sales forecast and initiated Phase 3 trials for new vaccines.
The positive financial results and the initiation of Phase 3 trials for new vaccines are likely to boost investor confidence in Moderna. The reiteration of the sales forecast suggests stability and potential growth, which could positively impact the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100